Our Mission is to Address Unmet Need in Inflammatory Bowel Disease with APX3330, A Systemic, Novel, Oral, Upstream Differentiated Investigational Drug
Our program is a clinical stage, oral small molecule drug candidate targeting upstream of TNFa, IL-23, a4b7, S1P, TL1A & JAKi biology, converging on validated pathways that enables combination with approved blockbuster drugs allowing broader anti-inflammatory effects.
Current Therapies Fail to Address the Systemic Drivers of IBD
Lacking Efficacy of Current Therapies is Apparent in Patient Response
- >50% of patients fail to reach remission on current advanced therapies at 1 year
- >30% of patients lose response or remain symptomatic (urgency, pain, and fatigue)
Sources: Solitano V, Jairath V, Magro F, Armuzzi A, Peyrin-Biroulet L, Danese S. Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality? Lancet Gastroenterol Hepatol. 2026. · Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1053–1062.
Inflammatory Bowel Disease
Crohn's Disease
(CD)
(CD)
1 Million
US
Ulcerative Colitis
(UC)
(UC)
1.3 Million
US
Over $15B US IBD Market with High Unmet Need
A growing global market where existing therapies leave meaningful room for a differentiated, combinable oral therapy.
7M
Global IBD Patients
Growing market with significant unmet need
>$15B
US Market (Sales)
$7B Ulcerative Colitis + $9B Crohn's Disease
8%
Projected CAGR
Growth projected through 2030
Sources: US Market Sales — FY2025 net sales, bottom up from company FY2025 results (AbbVie, J&J, Takeda) and SEC filings; estimated UC/CD split modeled by FDA approval timing per indication. Epidemiology: CDC; Lewis et al., Gastroenterology 2023;165(5):1197–1205.
Human Safety Signal
De-risked, Mid-stage Drug with a Positive Human Safety Signal
APX3330 has been studied across 3 indications in 14 Phase 1 and Phase 2 clinical trials, with approximately 400 patients dosed and no serious drug-related adverse events.
Expected Differentiated Profile for Single and Combination IBD Treatment with APX3330
Convenient and Accessible Oral Tablet
Attractive Safety Profile
Pain and Bowel Urgency Reduction
Preservation of Immune Response
Mucosal Barrier Integrity
Interested in learning more?
Contact our team for investor, partnership, and clinical inquiries, or explore our published science.